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Abstract
Prostaglandin E synthase (PGES) including isoenzymes of
membrane-associated PGES (mPGES)-1, mPGES-2, and
cytosolic PGES (cPGES) is the recently identified terminal
enzyme of the arachidonic acid cascade. PGES converts
prostaglandin (PG)H2 to PGE2 downstream of cyclooxygenase
(COX). We investigated the expression of PGES isoenzyme in
articular chondrocytes from patients with osteoarthritis (OA).
Chondrocytes were treated with various cytokines and the
expression of PGES isoenzyme mRNA was analyzed by the
reverse transcription–polymerase chain reaction and Northern
blotting, whereas Western blotting was performed for protein
expression. The subcellular localization of mPGES-1 was
determined by immunofluorescent microscopy. Conversion of
arachidonic acid or PGH2 to PGE2 was measured by enzyme-
linked immunosorbent assay. Finally, the expression of mPGES-
1 protein in OA articular cartilage was assessed by
immunohistochemistry. Expression of mPGES-1 mRNA in
chondrocytes was significantly induced by interleukin (IL)-1β or
tumor necrosis factor (TNF)-α, whereas other cytokines, such as
IL-4, IL-6, IL-8, IL-10, and interferon-γ, had no effect. COX-2 was
also induced under the same conditions, although its pattern of
expression was different. Expression of cPGES, mPGES-2, and
COX-1 mRNA was not affected by IL-1β or TNF-α. The
subcellular localization of mPGES-1 and COX-2 almost
overlapped in the perinuclear region. In comparison with 6-keto-
PGF1α  and thromboxane B2, the production of PGE2  was
greater after chondrocytes were stimulated by IL-1β or TNF-α.
Conversion of PGH2 to PGE2 (PGES activity) was significantly
increased in the lysate from IL-1β-stimulated chondrocytes and
it was inhibited by MK-886, which has an inhibitory effect on
mPGES-1 activity. Chondrocytes in articular cartilage from
patients with OA showed positive immunostaining for mPGES-
1. These results suggest that mPGES-1 might be important in
the pathogenesis of OA. It might also be a potential new target
for therapeutic strategies that specifically modulate PGE2
synthesis in patients with OA.
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Introduction
Osteoarthritis (OA) is the most common chronic articular
condition and is primarily characterized by the progressive
destruction of articular cartilage. Although OA is tradition-
ally defined as a non-inflammatory arthropathy, many
reports have suggested that proinflammatory cytokines
such as interleukin (IL)-1β and tumor necrosis factor (TNF)-
α might be important in this disease [1-3]. Stimulation of
chondrocytes by proinflammatory cytokines increases the
production of major cartilage-degrading enzymes, called
matrix metalloproteinases [4-6], inhibits the synthesis of
cartilage proteoglycans and/or type II collagen [7-9], stim-
ulates the production of reactive oxygen species such as
nitric oxide [10-12], and increases the production of
COX = cyclooxygenase; cPGES = cytosolic prostaglandin E synthase; DMEM = Dulbecco's modified Eagle's medium; ELISA = enzyme-linked immu-
nosorbent assay; FBS = fetal bovine serum; HRP = horseradish peroxidase; IL = interleukin; mPGES = membrane-associated prostaglandin E syn-
thase; OA = osteoarthritis; PBS = phosphate-buffered saline; PG = prostaglandin; PGES = prostaglandin E synthase; RT–PCR = reverse 
transcription–polymerase chain reaction; SDS = sodium dodecyl sulfate; TBS = Tris-buffered saline; TBS-T = TBS containing 0.1% Tween-20; TNF 
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prostaglandin (PG)E2 [13,14]. It was recently shown that
high levels of PGE2 production by OA tissues are observed
after stimulation by IL-1β, which might have a role in the
degeneration of bone and cartilage associated with OA
[15]. It was also reported that the nitric oxide-induced
death of OA chondrocytes was enhanced through the pro-
duction of PGE2 by the chondrocytes themselves [16].
In the PGE2 synthesis pathway, cyclooxygenase (COX) is a
key enzyme that metabolizes arachidonic acid to PGG2 and
PGH2. There are two isoforms of COX, which are desig-
nated COX-1 and COX-2 [17,18]. COX-1 is expressed
constitutively in various cells and tissues, and is important
in maintaining homeostasis. In contrast, COX-2 is induced
in inflammatory cells and tissues by various stimuli includ-
ing cytokines, suggesting that COX-2 has a key role in the
process of inflammation. Increased PGE2 production in
response to stimulation by proinflammatory cytokines coin-
cides with the upregulation of COX-2 expression.
PGE synthase (PGES) acts downstream of COX to cata-
lyze the conversion of PGH2 into PGE2 [19,20]. At least
three forms of human PGES have been cloned and charac-
terized, including membrane-associated PGES (mPGES)-
1 [21], mPGES-2 [22], and cytosolic PGES (cPGES) [23].
Among these, mPGES-1 was originally known as micro-
somal glutathione S-transferase 1-like 1 (MGST1-L1), and
it is a glutathione-dependent enzyme that shows coordi-
nated induction with COX-2 by inflammatory stimuli in vari-
ous cells and tissues [21,24]. We and others have reported
that mPGES-1 was coordinately induced with COX-2 by
IL-1β in synovial fibroblasts from patients with rheumatoid
arthritis [25-27]. It was also reported that mPGES-1 is
expressed in joint tissues isolated from animals with arthri-
tis [28,29]. Moreover, a recent study demonstrated that
mPGES-1-deficient mice showed a significant reduction of
the inflammatory features and histopathological changes
such as pannus formation and joint erosion of experimental
inflammatory arthritis [30]. Although the significance of
PGE2 in the pathophysiology of OA has been demon-
strated, the role of each PGES isoenzyme has not yet been
determined. Accordingly, we studied the effects of various
inflammatory cytokines on the expression of PGES isoen-
zymes in OA chondrocytes.
Materials and methods
Materials
Rabbit anti-human mPGES-1 polyclonal antibody, rabbit
anti-human cPGES polyclonal antibody, rabbit anti-human
COX-2 polyclonal antibody, PGE2, PGH2, and enzyme-
linked immunosorbent assay (ELISA) kits for PGE2, 6-keto-
PGF1α, and thromboxane (TX)B2 were all purchased from
Cayman Chemical Co. (Ann Arbor, MI). Mouse anti-human
COX-1 monoclonal antibody and MK-886 were purchased
from Wako Pure Chemical Industries (Osaka, Japan). Goat
anti-human COX-2 polyclonal antibody was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Horseradish
peroxidase (HRP)-conjugated goat anti-rabbit IgG, HRP-
conjugated goat anti-mouse IgG, tetramethylrhodamine β-
isothiocyanate-conjugated donkey anti-goat IgG, and fluo-
rescein isothiocyanate-conjugated donkey anti-rabbit IgG
were obtained from Jackson ImmunoResearch (West
Grove, PA). Dulbecco's modified Eagle's medium (DMEM),
fetal bovine serum (FBS), and TRIzol reagent were from Inv-
itrogen (Carlsbad, CA). Recombinant human IL-1β, TNF-α,
IL-4, IL-6, IL-8, IL-10, and interferon-γ were from BD Bio-
sciences (San Diego, CA). The Megaprime DNA labeling
system, [α-32P]dCTP, nylon membrane (Hybond N+), and
enhanced chemiluminescence reagent were purchased
from Amersham Pharmacia Biotech (Little Chalfont,
Bucks., UK), and poly(vinylidene difluoride) membrane
(Immobilon-P) was obtained from Millipore (Bedford, MA).
Preparation of cells
Cartilage samples were obtained at the time of joint
replacement surgery from patients with OA who fulfilled the
American College of Rheumatology criteria for this disease
[31]. These experiments were performed in accordance
with a protocol approved by the ethics committee of St
Marianna University, and all patients gave written consent
to the use of their tissues for this research.
Chondrocytes were prepared as described elsewhere
[32]. In brief, cartilage samples were minced and digested
with 1 mg/ml collagenase in DMEM for 18 h at 37°C, fil-
tered through a nylon mesh, and washed extensively. Then
the isolated chondrocytes were seeded at a high density in
tissue culture flasks coated with type I collagen and were
incubated in DMEM containing 10% FBS, 100 units/ml
penicillin, and 100 µg/ml streptomycin at 37°C under an
a t m o s p h e r e  o f  5 %  C O 2. At confluence, the cells were
detached and passaged, and the second-passage cells
were used in subsequent experiments. The chondrocytes'
phenotype was assessed by analyzing the expression of
type II collagen with the reverse transcription–polymerase
chain reaction (RT–PCR) (Fig. 1). OA synovial fibroblasts
and normal dermal fibroblasts were prepared as described
previously [25,33].
RT–PCR
Cells were seeded into the wells of a six-well plate coated
with type I collagen at a density of 5 × 104 cells/cm2 in cul-
ture medium containing 1% FBS, and then were cultured
under various conditions. RNA from the cells was extracted
with TRIzol reagent in accordance with the manufacturer's
instructions. Reverse transcription was performed with a
SuperScript preamplification system (Invitrogen, Carlsbad,
CA), in accordance with the manufacturer's instructions,
with 1 µg of total RNA from the cells as a template. Equal
amounts of each reverse-transcription product wereAvailable online http://arthritis-research.com/content/6/4/R355
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amplified by PCR with HotStarTaq polymerase (Qiagen,
Valencia, CA). After initial denaturation at 95°C for 15 min,
PCR involved amplification cycles of 30 s at 95°C, 30 s at
56°C, and 45 s at 72°C, followed by elongation for 5 min
at 72°C. The sequences of the primers, the size of the PCR
products, and the number of amplification cycles are
shown in Table 1. The amplified cDNA fragments were
resolved by electrophoresis on 1.5% (w/v) agarose gel,
and were detected under ultraviolet after staining of the gel
with ethidium bromide.
Northern blot analysis
Cells were seeded into the wells of a six-well plate coated
with type I collagen at a density of 5 × 104 cells/cm2 in cul-
ture medium containing 1% FBS, and were then cultured
under various conditions. Northern blotting was performed
as described previously [25]. Total RNA (4 µg) was
extracted from the cells with TRIzol reagent and was sub-
jected to electrophoresis on 1% formaldehyde/agarose
gel, followed by transfer to a Hybond N+ membrane and
hybridization with cDNA probes that had been labeled with
[α-32P]dCTP by random priming. After hybridization, the
membranes were washed and the RNA bands were
detected by autoradiography.
Western blot analysis
Cells (at a density of 5 × 104 cells/cm2) were cultured
under various conditions in medium containing 1% FBS.
Subsequently, the cells were lysed in Tris-buffered saline
(TBS) containing 0.1% sodium dodecyl sulfate (SDS), and
the protein content of the lysates was determined with the
bicinchoninic acid protein assay reagent (Pierce, Rockford,
IL), with bovine serum albumin as the standard. Cell lysates
were adjusted to 5 µg of protein and were then applied to
SDS-polyacrylamide gels (10–20%) for electrophoresis,
as reported previously [25]. Next, the proteins were elec-
troblotted onto Immobilon-P poly(vinylidene difluoride)
membranes with a semidry blotter (Atto, Tokyo, Japan).
After the membranes had been blocked in 10 mM TBS
containing 0.1% Tween-20 (TBS-T) and 5% skimmed milk,
the primary antibody (rabbit anti-human mPGES-1 anti-
body, rabbit anti-human cPGES antibody, mouse anti-
human COX-1 antibody, or rabbit anti-human COX-2 anti-
body) was added at a dilution of 1:500 (mPGES-1 and
cPGES) or 1:200 (COX-1 and COX-2) in TBS-T, and incu-
bation was performed for 1.5 h. After the membranes had
been washed with TBS-T, the secondary antibody (HRP-
conjugated goat anti-rabbit antibody or HRP-conjugated
goat anti-mouse antibody) was added (at a dilution of
1:10,000 or 1:5,000, respectively, in TBS-T) and incuba-
tion was performed for 1 h. After further washing with TBS-
T, protein bands were detected with an enhanced chemilu-
minescence Western blot analysis system.
Immunofluorescent microscopy
Immunofluorescent microscopy was performed as reported
previously [25]. In brief, cells were seeded at a density of
2.5 × 104 cells/cm2 onto culture slides coated with type I
collagen and were incubated with or without 1 ng/ml IL-1β
for 48 h. After removal of the supernatants, the cells were
fixed with 4% (w/v) paraformaldehyde in phosphate-buff-
ered saline (PBS) for 30 min at 4°C. Then the cells were
permeabilized with 0.1% Triton-X in PBS for 3 min. After
blocking with 1% (w/v) bovine serum albumin in PBS for 1
h at 20–25°C, rabbit anti-human mPGES-1 polyclonal anti-
body and goat anti-human COX-2 polyclonal antibody
(premixed so that the final dilutions were, respectively,
1:100 and 1:250 in PBS containing 1% albumin) were
added and incubation was done for 1.5 h at 20–25°C. After
washing with PBS, tetramethylrhodamine β-isothiocyanate-
conjugated and fluorescein isothiocyanate-conjugated
secondary antibodies were added at 1:50 dilution in PBS
containing 1% albumin, and incubated for 1 h. Then the
Figure 1
Phenotypic features of chondrocytes Phenotypic features of chondrocytes. (a) Morphology of chondrocytes 
and synovial fibroblasts from patients with osteoarthritis. (b) Chondro-
cytes from four patients with osteoarthritis were incubated for 12 h. 
Total RNA from the cells was subjected to reverse transcription–
polymerase chain reaction (RT–PCR) for type I collagen, type II colla-
gen, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as 
described in Materials and methods. Synovial fibroblasts and dermal 
fibroblasts were used as controls. (c) Chondrocytes from osteoarthritis 
patients were incubated with IL-1β (1 ng/ml) or tumor necrosis factor-α 
(TNFα; 10 ng/ml) for 12 h. Total RNA from the cells was subjected to 
RT–PCR for type I collagen, type II collagen, and GAPDH, as 
described in Materials and methods. Representative results from three 
patients are shown here.Arthritis Research & Therapy    Vol 6 No 4    Kojima et al.
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glass slides were sealed under coverslips using Vectash-
ield Mounting Medium (Vector Laboratories, Burlingame,
CA) and examined under an IX71 microscope connected
to a Cool SNAP HQ digital camera (Olympus, Tokyo,
Japan).
Conversion of arachidonic acid to PGE2, 6-keto-PGF1α, 
and TXB2
Cells stimulated with IL-1β or TNF-α were washed with
DMEM and incubated for a further 30 min with 3 µM ara-
chidonic acid, as reported previously [25,34]. The culture
medium was then harvested, and the concentrations of
PGE2, 6-keto-PGF1α (a stable metabolite of PGI2), and
TXB2 (a stable metabolite of TXA2) were measured by
ELISA.
Measurement of PGES activity
PGES activity was measured by assessment of the conver-
sion of PGH2 to PGE2, as reported previously [25,35]. In
brief, cells (at a density of 5 × 104 cells/cm2) were cultured
under various conditions in medium containing 1% FBS.
The cells were then scraped off the dish and lysed by son-
ication (twice for 10 s each at 1 min intervals) in 100 µl of
1 M Tris–HCl (pH 8.0). After centrifugation of the lysate at
15,000 g for 1 min at 4°C, the supernatant was used to
measure PGES activity. For assessment of PGES activity,
an aliquot of each supernatant equivalent to 50 µg of pro-
tein was incubated with 2 µg of PGH2 for 30 s at 24°C in
0.1 ml of 1 M Tris–HCl containing 2 mM glutathione, in the
absence or presence of MK-886. The reaction was termi-
nated by the addition of 100 mM FeCl2; the reaction mix-
ture was then left to stand at 20–25°C for 15 min. After
centrifugation of the reaction mixture, the PGE2 concentra-
tion in the supernatant was measured with an ELISA kit.
Measurement of prostaglandins in culture medium
Cells were seeded at a density of 5 × 104 cells/cm2 in cul-
ture medium containing 1% FBS and were incubated with
IL-1β for 48 h. In experiments involving treatment with MK-
886, it was added 30 min before IL-1β. The culture
supernatant was then harvested and the PGE2 concentra-
tion was measured with an ELISA kit.
Immunohistochemical analysis
Tissue sections were incubated for 5 min with 3% (v/v)
H2O2. After blocking with 1% (w/v) bovine serum albumin
in PBS for 30 min at 20–25°C, rabbit anti-human mPGES
antibody or goat anti-human COX-2 antibody (diluted
1:100 or 1:200, respectively, in PBS containing 1% albu-
min) was added and incubation was performed for 1.5 h at
20–25°C. After being washed, the sections were incu-
bated with the biotinylated secondary antibody, followed by
streptavidin–HRP complex and 3,3'-dimaminobenzidine
tetrahydrochloride in accordance with the manufacturer's
protocol (LSAB staining kit; Dako, Carpinteria, CA). As
adsorption controls, primary antibodies against mPGES-1
and COX-2 were used that had been previously reacted
with mPGES-1 (10 µg/ml) or COX-2 peptide (10 µg/ml),
respectively. In addition, rabbit anti-human mPGES-1 was
replaced with normal rabbit IgG as a negative control.
Statistical analysis
Results are expressed as means ± SD for triplicate experi-
ments, and representative results from three independent
Table 1
Oligonucleotide primers used in the reverse transcription-polymerase chain reaction
Target gene encoding Product length (bp) Primer (5' → 3')a Cycle
Type I collagen 614 CAA CGG TGC TCC TGG TGA AG
GCT GGT CAG CCC TGT AGA AG
32
Type II collagen 507 TCA ACA ACC AGA TTG AGA GCA
ACG TGA ACC TGC TAT TGC CCT
32
mPGES-1 459 ATG CCT GCC CAC AGC CTG GT
TCA CAG GTG GCG GGC CGC TT
26
mPGES-2 502 GCA GCT GAC CCT GTA CCA GT
CTC GCG GAC AAT GTA GTC AA
32
cPGES 485 ATG CAG CCT GCT TCT GCA AA
CCT TAC TCC AGA TCT GGC AT
30
COX-1 401 CTT TCT CCA ACG TGA GCT ATT
GTG CAT CAA CAC AGG CGC CTC TTC
32
COX-2 1157 AGA CAG ATC ATA AGC GAG GGC C
ACT TGC ATT GAT GGT GAC TGT
28
GAPDH 598 CCA CCC ATG GCA AAT TCC ATG GCA
TCT AGA CGG CAG GTC AGG TCC ACC
26
COX, cyclooxygenase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; mPGES, membrane-associated prostaglandin E synthase; cPGES, 
cytosolic prostaglandin E synthase. aFor each target gene, the upper primer is the forward primer and the lower primer is the reverse primer.Available online http://arthritis-research.com/content/6/4/R355
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patients are shown. Statistical analysis for triplicate experi-
ments was performed with Tukey's multiple comparison
test; P < 0.05 was considered significant.
Results
Phenotypic features of chondrocytes
Morphology and collagen mRNA expression were exam-
ined for assessment of the chondrocyte phenotype. The
morphology of chondrocytes used in this study was obvi-
ously different from that of synovial fibroblasts (Fig. 1a).
Type I collagen mRNA was expressed in chondrocytes as
well as synovial fibroblasts and dermal fibroblasts. In con-
trast, expression of type II collagen mRNA was detected
only in chondrocytes, as shown in Fig. 1b. Moreover,
expression of type II collagen mRNA as well as type I colla-
gen mRNA in chondrocytes was maintained after stimula-
tion of IL-1β or TNF-α for 12 h (Fig. 1c).
Effect of cytokines on expression of mRNAs for PGES 
and COX isoenzymes in chondrocytes
The expression of mRNA for mPGES-1 and COX-2 in
chondrocytes from patients with OA was assessed by RT–
PCR after the cells had been treated with various cytokines
for 12 h. As shown in Fig. 2a, TNF-α or IL-1β induced the
expression of mPGES-1 and COX-2 mRNA in chondro-
cytes. In contrast, IL-4, IL-6, IL-8, IL-10, and interferon-γ all
had no effect on the expression of mPGES-1 or COX-2
mRNA.
We next examined the induction of mRNA for PGES and
COX isoenzymes by IL-1β or TNF-α in chondrocytes from
four patients with OA (Fig. 2b). Expression of mPGES-1
and COX-2 mRNA was significantly induced by IL-1β or
TNF-α in chondrocytes from all four patients. In contrast,
mRNA for mPGES-2, cPGES, and COX-1 was constitu-
tively expressed in unstimulated chondrocytes, and expo-
sure to IL-1β or TNF-α had little effect on the expression of
these mRNAs. The pattern of mRNA expression for each
enzyme was similar in all four patients.
Subsequently, we examined the effect of various concen-
trations of IL-1β and TNF-α on mPGES-1 and COX-2
mRNA by Northern blot analysis. As shown in Fig. 3,
expression of mPGES-1 and COX-2 mRNA was induced
by IL-1β in a concentration-dependent manner. TNF-α also
induced expression of mPGES-1 mRNA, but had a weaker
effect than IL-1β. The effect of TNF-α on the expression of
COX-2 mRNA was also weaker than that of IL-1β.
Figure 2
Effects of cytokines on the expression of prostaglandin E synthase  (PGES) and cyclooxygenase (COX) isoenzyme mRNAs in  chondrocytes Effects of cytokines on the expression of prostaglandin E synthase 
(PGES) and cyclooxygenase (COX) isoenzyme mRNAs in chondro-
cytes. (a) Chondrocytes from patients with osteoarthritis were incu-
bated with interleukin (IL)-1β (1 ng/ml), tumour necrosis factor (TNFα; 
10 ng/ml), IL-4 (10 ng/ml), IL-6 (10 ng/ml), IL-8 (10 ng/ml), IL-10 (10 
ng/ml), or interferon-γ (IFNγ; 100 ng/ml) for 12 h. Total RNA from the 
cells was subjected to reverse transcription–polymerase chain reaction 
(RT–PCR) for membrane-associated PGES (mPGES)-1, COX-2, and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as described 
in Materials and methods. Representative results from three patients 
are shown here. (b) Chondrocytes from four patients with osteoarthritis 
were incubated with IL-1β (1 ng/ml) or TNF-α (10 ng/ml) for 12 h. Total 
RNA from the cells was subjected to RT–PCR for mPGES-1, mPGES-
2, cytosolic PGES (cPGES), COX-1, COX-2, and GAPDH, as 
described in Materials and methods. Representative results are shown 
here.
Figure 3
Expression of membrane-associated prostaglandin E synthase-1  (mPGES-1) and cyclooxygenase-2 (COX-2) mRNA in cytokine-stimu- lated chondrocytes Expression of membrane-associated prostaglandin E synthase-1 
(mPGES-1) and cyclooxygenase-2 (COX-2) mRNA in cytokine-stimu-
lated chondrocytes. Chondrocytes from patients with osteoarthritis 
were incubated with interleukin-1β (IL-1β; 0.01–10 ng/ml) or tumor 
necrosis factor-α (TNF-α; 0.01–10 ng/ml) for 12 h. Total RNA from the 
cells was subjected to Northern blot analysis for mPGES-1, COX-2, 
and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as 
described in Materials and methods. Representative results from three 
patients are shown.Arthritis Research & Therapy    Vol 6 No 4    Kojima et al.
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Expression of mPGES-1 and COX-2 protein in cytokine-
stimulated chondrocytes
Expression of mPGES-1 and COX-2 protein in chondro-
cytes stimulated with IL-1β or TNF-α was investigated by
Western blot analysis and immunofluorescent microscopy
(Fig. 4). As shown in Fig. 4a, both mPGES-1 and COX-2
protein were induced by IL-1β and TNF-α, similar to the
results for mRNA expression shown in Fig. 3. Colocaliza-
tion of these enzymes was observed in the perinuclear
region of IL-1β-stimulated chondrocytes (Fig. 4b).
Production of PGE2, 6-keto-PGF1α, and TXB2 in cytokine-
stimulated chondrocytes
To determine the profile of PG synthesis in OA chondro-
cytes, cells were exposed to various concentrations of IL-
1β (0.01–10 ng/ml) or TNF-α (0.01–10 ng/ml) for 24 h and
the conversion of exogenous arachidonic acid to PGE2, 6-
keto-PGF1α (a stable metabolite of PGI2), and TXB2 (a sta-
ble metabolite of TXA2) was measured by ELISA. As shown
in Fig. 5a, PGE2 synthesis was markedly increased by IL-1β
or TNF-α (to a smaller extent) in a concentration-dependent
manner. The pattern of PGE2 production was similar to
results shown in Fig. 2. In contrast, the changes in 6-keto-
PGF1α (Fig. 5b) and TXB2 (Fig. 5c) after the addition of IL-
1β or TNF-α were almost negligible compared with the
effect on PGE2.
Time course of the expression of PGES and COX 
isoenzymes in IL-1β-stimulated chondrocytes
The expression of mRNA (Fig. 6a) and protein (Fig. 6b) for
PGES and COX isoenzymes at various times after stimula-
tion with IL-1β was assessed by Northern and Western
blotting, respectively. Expression of mPGES-1 mRNA
showed a gradual increase, reaching a maximum after 24–
48 h of exposure to IL-1β. Expression of mPGES-1 protein
showed a slight increase at 12 h, and then gradually
increased until at least 72 h. In contrast, COX-2 mRNA
increased rapidly after the start of IL-1β stimulation, and its
expression remained maximal until 48 h. The COX-2 pro-
tein level also showed a rapid increase within 6 h and
expression was maximal between 12 and 48 h; it
decreased again at 72 h. Expression of mPGES-1 was
delayed compared with that of COX-2. In contrast, the lev-
els of cPGES and COX-1 mRNA and protein were not
affected by IL-1β.
Induction of PGES activity in IL-1β-stimulated 
chondrocytes
To investigate whether PGES enzymatic activity was
upregulated by IL-1β, we measured the conversion of
Figure 4
Expression of membrane-associated prostaglandin E synthase  (mPGES-1) and cyclooxygenase-2 (COX-2) protein in cytokine-stimu- lated chondrocytes Expression of membrane-associated prostaglandin E synthase 
(mPGES-1) and cyclooxygenase-2 (COX-2) protein in cytokine-stimu-
lated chondrocytes. (a) Chondrocytes from osteoarthritis patients were 
incubated for 48 h with interleukin-1β (IL-1β; 0.01–10 ng/ml) or tumour 
necrosis factor-α (TNFα; 0.01–10 ng/ml). Protein from the cells was 
subjected to Western blot analysis for mPGES-1 and COX-2. (b) 
Chondrocytes from osteoarthritis patients were incubated for 48 h with 
IL-1β (1 ng/ml) or TNF-α (10 ng/ml). The cells were then double-immu-
nostained with tetramethylrhodamine β-isothiocyanate for mPGES-1 
(upper row) and fluorescein isothiocyanate for COX-2 (lower row), and 
were examined under a Fluoview laser fluorescence microscope. Rep-
resentative findings from three patients are shown here.
Figure 5
Production of prostaglandin E2 (PGE2) (a), 6-keto-PGF1α (b), and  thromboxane (TX)B2 (c) in cytokine-stimulated chondrocytes Production of prostaglandin E2 (PGE2) (a), 6-keto-PGF1α (b), and 
thromboxane (TX)B2 (c) in cytokine-stimulated chondrocytes. Chondro-
cytes from osteoarthritis patients were incubated for 24 h with inter-
leukin-1β (IL-1β; 0.01–10 ng/ml, filled circles) or tumor necrosis factor-
α (0.01–10 ng/ml, open circles). After being washed, the cells were 
incubated for a further 30 min with 3 µM arachidonic acid; the PGE2, 6-
keto-PGF1α (a stable metabolite of PGI2), and TXB2 (a stable metabolite 
of TXA2) concentrations in the medium were then measured by enzyme-
linked immunosorbent assay. Data are means ± SD for triplicate cul-
tures, and representative results from three patients are shown. *P < 
0.01 compared with untreated control cells.Available online http://arthritis-research.com/content/6/4/R355
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PGH2 to PGE2 in lysates prepared from IL-1β-stimulated
chondrocytes at various times (Fig. 7a). PGES activity
increased gradually until 72 h after the start of IL-1β stimu-
lation. These results matched the pattern of mPGES-1 pro-
tein expression (Fig. 6b).
It was reported that MK-886 could inhibit mPGES-1 activity
in mPGES-1 transfected cells [28]. To evaluate the contri-
bution of mPGES-1 to the IL-1β-induced increase of PGES
activity in chondrocytes, we examined the effect of MK-886
on PGES activity in chondrocyte lysates. As shown in Fig.
7b, PGES activity in lysates from unstimulated chondro-
cytes was very low, and it was not affected by MK-886
alone. In contrast, the increased level of PGES activity in
lysates prepared from IL-1β-stimulated chondrocytes was
inhibited by MK-886 in a concentration-dependent manner.
These results suggested that the induction of PGES activ-
ity by IL-1β in chondrocytes was dependent mainly on the
enzymatic activity of inducible mPGES-1 rather than on
constitutive mPGES-2 and cPGES.
Effect of MK-886 on PGE2 production in IL-1β-stimulated 
chondrocytes
We next examined the effect of MK-886 on endogenous
PGE2  production in IL-1β-stimulated chondrocytes.
Chondrocytes were incubated with IL-1β for 48 h in the
absence or presence of MK-886. As shown in Fig. 8,
endogenous PGE2 production by OA chondrocytes was
significantly increased after stimulation with IL-1β. When
chondrocytes were cultured with IL-1β in the presence of
MK-886, there was significant inhibition of PGE2 produc-
tion in a concentration-dependent manner. Microscopy of
the cells revealed severe toxicity of MK-886 at 30 µM (data
not shown).
Expression of mPGES-1 protein in articular cartilage 
from patients with OA
Articular cartilage obtained from patients with OA was fixed
in formaldehyde, embedded in paraffin, and cut into serial
sections that were immunostained with antibody against
mPGES-1 or COX-2. Chondrocytes in the articular
cartilage from patients with OA were stained by the anti-
Figure 6
Time course of the expression of prostaglandin E synthase (PGES) and  cyclooxygenase (COX) isoenzymes in chondrocytes stimulated with  interleukin-1β (IL-1β) Time course of the expression of prostaglandin E synthase (PGES) and 
cyclooxygenase (COX) isoenzymes in chondrocytes stimulated with 
interleukin-1β (IL-1β). Chondrocytes from osteoarthritis patients were 
incubated with IL-1β (1 ng/ml) for the indicated durations. (a) Total 
RNA from the cells was subjected to Northern blot analysis for mem-
brane-associated PGES-1 (mPGES-1), cytosolic PGES (cPGES), 
COX-1, COX-2, and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). (b) Protein from the cells was subjected to Western blot 
analysis for mPGES-1, cPGES, COX-1, and COX-2. Representative 
results from three patients are shown here.
Figure 7
Induction of prostaglandin E synthase (PGES) activity in chondrocytes  stimulated with IL-1β (IL-1β) Induction of prostaglandin E synthase (PGES) activity in chondrocytes 
stimulated with IL-1β (IL-1β). (a) For estimation of the PGES activity 
that produces prostaglandin (PG)E2 from PGH2, exogenous PGH2 (2 
µg) was added to lysates of chondrocytes that had been incubated 
with (filled circles) or without (open circles) IL-1β (1 ng/ml) for the indi-
cated durations. The lysates were then incubated at 24°C for 30 s in 
the presence of reduced glutathione, the reaction was stopped with 
100 mM FeCl2, and the PGE2 concentration was measured by enzyme-
linked immunosorbent assay. Spontaneous conversion of PGH2 to 
PGE2 in the absence of cell lysates was subtracted from each result. 
Data are means ± SD for triplicate cultures; representative results from 
three patients are shown. *P < 0.01 and †P < 0.05 compared with 0 h. 
(b) Chondrocytes were incubated with or without IL-1β (1 ng/ml) for 48 
h. Then the PGES activity of the cell lysates in the presence or absence 
of MK-886 (1–100 µM) was measured as described in Materials and 
methods, and calculated as a percentage of the control value (IL-1β 
alone). Data are means ± SD for triplicate experiments; representative 
results from three patients are shown. #P < 0.01, untreated control 
compared with IL-1β alone; *P < 0.01, IL-1β alone compared with IL-1β 
plus MK-886.Arthritis Research & Therapy    Vol 6 No 4    Kojima et al.
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body against mPGES-1 (Fig. 9a). When the absorption
control using mPGES-1 peptide was tested (Fig. 9b),
mPGES-1 immunostaining was almost completely abol-
ished. In addition, no mPGES-1 immunostaining was
observed when rabbit anti-human mPGES-1 was replaced
by normal rabbit IgG (Fig. 9c). COX-2 immunostaining was
also positive in the chondrocytes (Fig. 9d), whereas the
absorption control using COX-2 peptide (Fig. 9e) showed
no COX-2 immunostaining.
Discussion
In this study we demonstrated that mPGES-1 is a key
enzyme in the regulation of PGE2 production in cytokine-
stimulated chondrocytes from patients with OA. Although
several studies on the induction of COX-2 and its regula-
tory mechanism in chondrocytes have already been pub-
lished [16,36,37], this is the first report that mPGES-1,
located downstream of COX-2, is induced in chondrocytes
by cytokine stimulation. Among the various cytokines that
we tested, IL-1β and TNF-α caused the induction of both
mPGES-1 expression and COX-2 expression. In addition
we demonstrated mPGES-1 and COX-2 immunostaining
of chondrocytes in articular cartilage from patients with OA.
There have been reports of a high level of IL-1β and TNF-α
expression on the surface of OA cartilage, and the
production of IL-1β in OA tissues seems to be correlated
with the extent of cartilage damage [4,38-40]. It was also
reported that IL-1β expression is increased in synovial
membrane tissues obtained from patients with OA at all
stages of the disease [5,41]. Our results suggested that
expression of mPGES-1 and COX-2 in chondrocytes from
patients with OA might be promoted by endogenous IL-1β
and TNF-α released from cartilage and/or synovial tissue.
Long-term culture and/or multiple passages of chondro-
cytes generally induce dedifferentiation of the cells. The
existence of type II collagen, which is highly specific to
chondrocytes, is one of the major phenotypic characteriza-
tions of this cell type; dedifferentiated chondrocytes lose
the expression of type II collagen [42]. In our study, the
chondrocytes that we used expressed type II collagen and
were clearly distinguished from synovial fibroblasts and
dermal fibroblasts. Thus, we estimated that the
chondrocytes in our study were maintained in a differenti-
ated condition.
We also studied the profile of PG synthesis in chondro-
cytes. PGE2 synthesis was markedly induced by IL-1β or
TNF-α, whereas 6-keto-PGF1α and TXB2 synthesis were
almost negligible in comparison. These results suggest that
terminal PG synthase downstream of COX is important for
deciding which PG is synthesized. In this study we showed
that the expression of mPGES-1 and COX-2 was markedly
induced by IL-1β in parallel with an increase in PGE2 syn-
thesis. In contrast, PGI synthase and TX synthase mRNAs
were detectable in chondrocytes by RT–PCR but were not
induced by IL-1β (data not shown). Moreover, MK-886,
which has an inhibitory effect on mPGES-1 activity [28],
significantly inhibited IL-1β-induced PGES activity in
lysates from IL-1β-stimulated chondrocytes. This inhibitor
also reduced PGE2 production by intact chondrocytes after
stimulation by IL-1β. These results suggest that the induc-
tion of mPGES-1 might be necessary for substantial PGE2
production by chondrocytes in response to proinflamma-
Figure 8
Effect of MK-886 on endogenous prostaglandin E2 (PGE2) production  in chondrocytes stimulated with IL-1β (IL-1β) Effect of MK-886 on endogenous prostaglandin E2 (PGE2) production 
in chondrocytes stimulated with IL-1β (IL-1β). Chondrocytes from 
patients with osteoarthritis were incubated with IL-1β in the presence of 
MK-886 (1 or 10 µM) for 48 h. The PGE2 concentration of the medium 
was then measured by enzyme-linked immunosorbent assay and calcu-
lated as a percentage of the control value (IL-1β alone). Data are means 
± SD for triplicate experiments; representative results from three 
patients are shown. #P < 0.01, untreated control compared with IL-1β 
alone; *P < 0.01, IL-1β alone compared with IL-1β plus MK-886.
Figure 9
Expression of membrane-associated prostaglandin E synthase-1  (mPGES-1) and cyclooxygenase-2 (COX-2) protein in articular carti- lage sections from osteoarthritis patients Expression of membrane-associated prostaglandin E synthase-1 
(mPGES-1) and cyclooxygenase-2 (COX-2) protein in articular carti-
lage sections from osteoarthritis patients. Paraffin-embedded section of 
cartilage from osteoarthritis patients were subjected to immunostaining 
for mPGES-1 (a) and COX-2 (d). As adsorption controls for mPGES-1 
(b) and COX-2 (e), primary antibodies that had been reacted with 
mPGES-1 and COX-2 peptide (10 µg/ml) were used, respectively. As 
a negative control for mPGES-1, rabbit anti-human mPGES-1 was 
replaced with normal rabbit IgG (c). Representative findings from three 
patients are shown here.Available online http://arthritis-research.com/content/6/4/R355
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tory stimuli. However, mPGES-1 is a member of the
MAPEG (membrane-associated proteins involved in
eicosanoid and glutathione metabolism) family, which also
contains 5-lipoxygenase-activating protein and leukotriene
C4 synthase. It has been shown that MK-886 inhibits not
only mPGES-1 but also 5-lipoxygenase-activating protein
[43] and LTC4 synthase [44]. Alternative specific methods
for inhibiting mPGES-1 therefore remain to be studied.
Immunohistochemistry revealed that mPGES-1 and COX-
2 protein colocalized to the perinuclear region of IL-1β-
stimulated chondrocytes. We recently reported that
mPGES-1 and COX-2 also showed perinuclear colocaliza-
tion in IL-1β-stimulated rheumatoid arthritis synovial fibrob-
lasts [25]. Murakami and colleagues showed that mPGES-
1 and COX-2 are functionally linked by using an mPGES-1
and COX-2 transfected cell line [24]. Colocalization of
mPGES-1 and COX-2 might be related to the preferential
increase of PGE2 production after IL-1β stimulation due to
functional linkage between these two enzymes in
chondrocytes.
The present study showed that the induction of mPGES-1
expression in chondrocytes was delayed compared with
that of COX-2 and that it persisted for longer after stimula-
tion with IL-1β. We previously found that increased expres-
sion of mPGES-1 was delayed in a similar fashion in IL-1β-
stimulated rheumatoid arthritis synovial fibroblasts [25].
This coordinated expression of mPGES-1 and COX-2 over
time might sustain higher PGE2 production in OA chondro-
cytes. The different profiles of mPGES-1 and COX-2
expression also imply that regulation of these enzymes
occurs through different pathways in chondrocytes. It was
recently shown that mPGES-1 expression in response to
various stimuli is regulated by a transcription factor, early
growth response factor-1 [45], which was reported to bind
to the proximal GC box in the mPGES-1 gene promoter. If
different transcription factors are associated with mPGES-
1 and COX-2, this might help to explain the different time
course of the expression of these enzymes in IL-1β-stimu-
lated chondrocytes.
Cartilage damage is considered to be a major cause of OA,
and chondrocytes seem to have a fundamental role in the
pathogenesis of this condition [46]. It was reported that
cartilage is the main target of cytokines such as IL-1β and
TNF-α in OA, and it seems that activated chondrocytes
might be a major source of various inflammatory mediators
associated with the progressive destruction of articular car-
tilage [47,48]. Accordingly, the induction of mPGES-1 in
cytokine-activated chondrocytes and the subsequent
increase of PGE2 production might be important in the
pathogenesis of OA. mPGES-1 is a specific enzyme that
only catalyzes PGE2 production from PGH2. mPGES-1
might therefore be a potential new target for therapeutic
strategies to specifically control the PGE2 synthesis asso-
ciated with inflammation in patients with OA and other
inflammatory diseases.
Conclusion
mPGES-1 was upregulated by proinflammatory cytokines
in OA chondrocytes and was one of the key enzymes in the
regulation of PGE2 production. mPGES-1 might be impor-
tant in articular inflammation with cytokine-stimulated con-
ditions in patients with OA.
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